A Study to See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD)

NCT04782258 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Autosomal Recessive Polycystic Kidney (ARPKD)

Interventions

DRUG: Tolvaptan Suspension
DRUG: Tolvaptan Tablets

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.